Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:ageRange |
18 Years and older
|
| gptkbp:clinicalTrialPhase |
Phase 1
|
| gptkbp:clinicalTrialsGovIdentifier |
gptkb:NCT05149502
|
| gptkbp:condition |
Advanced Solid Tumors
|
| gptkbp:eligibility |
Adults with advanced solid tumors
|
| gptkbp:enrollment |
80
|
| gptkbp:estimatedPrimaryCompletionDate |
December 2024
|
| gptkbp:estimatedStudyCompletionDate |
December 2024
|
| gptkbp:gender |
All
|
| https://www.w3.org/2000/01/rdf-schema#label |
NCT05149502
|
| gptkbp:intervention |
gptkb:TNG348
Single Group Assignment |
| gptkbp:location |
gptkb:United_States
|
| gptkbp:mask |
None (Open Label)
|
| gptkbp:officialName |
A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TNG348 in Patients With Advanced Solid Tumors
|
| gptkbp:purpose |
Treatment
|
| gptkbp:sponsor |
Tango Therapeutics, Inc.
|
| gptkbp:startDate |
December 2021
|
| gptkbp:studyType |
Interventional
|
| gptkbp:bfsParent |
gptkb:COMP360_(psilocybin_therapy)
|
| gptkbp:bfsLayer |
8
|